Jan
31
2012
0

Kalydeco – A Cystic Fibrosis Treatment

Originally posted in Cystic Fibrosis News From Medical News Today

Kalydeco has been approved by the Food And Drug Administration (FDA) to treat a vicious type of Cystic Fibrosis (CF). CF is a deadly recessive disease which targets the lungs, but can also harm the liver, pancreas, and intestine. It occurs from the unusual transport of chloride and sodium across the epithelium, causing mucus buildup in the lungs, and thick secretions…

Written by Cystic Fibrosis News From Medical News Today in: Cystic Fibrosis |

Jan
31
2012
0

Bronchoalveolar Lavage And Lung Clearance Index Detects Early Cystic Fibrosis Lung Disease

Originally posted in Cystic Fibrosis News From Medical News Today

The lung clearance index (LCI) is a sensitive non-invasive marker of early lung disease in young children with cystic fibrosis (CF), according to a new study from Australian researchers…

Written by Cystic Fibrosis News From Medical News Today in: Cystic Fibrosis |

Jan
30
2012
0

Early Cystic Fibrosis Detected Using Bronchoalveolar Lavage And Lung Clearance Index

Originally posted in Cystic Fibrosis News From Medical News Today

According to a new Australian study published online before he print publication in the American Thoracic Society’s American Journal of Respiratory and Critical Care Medicine, the lung clearance index (LCI) is a sensitive, non-invasive marker of early lung disease in young children with cystic fibrosis (CF)…

Written by Cystic Fibrosis News From Medical News Today in: Cystic Fibrosis |

Dec
20
2011
0

Lung Function In CF Improved By Long-Term Inhaled Dry Powder Mannitol

Originally posted in Cystic Fibrosis News From Medical News Today

Adding inhaled dry powder mannitol to standard therapy for cystic fibrosis produced sustained improvement in lung function for up to 52 weeks, according to a new study. Along with the treatment’s efficacy and good safety profile, the convenience and ease of administration of mannitol treatment may improve adherence with therapy in these patients…

Written by Cystic Fibrosis News From Medical News Today in: Cystic Fibrosis |

Dec
19
2011
0

Cystic Fibrosis – Inhaling Mannitol Plus Standard therapy Improves Lung Function

Originally posted in Cystic Fibrosis News From Medical News Today

A new study found that the combination of inhaled dry powder mannitol with standard therapy for cystic fibrosis resulted in maintained improvement in lung function for 12 months. In addition to being effective and safe, the easy administration of the treatment might help enhance adherence with treatment in individuals suffering with the condition…

Written by Cystic Fibrosis News From Medical News Today in: Cystic Fibrosis |

Dec
19
2011
0

Inhaled Dry Powder Mannitol Improves Lung Function In CF

Originally posted in Cystic Fibrosis News From Medical News Today

Adding inhaled dry powder mannitol to standard therapy for cystic fibrosis produced sustained improvement in lung function for up to 52 weeks, according to a new study. Along with the treatment’s efficacy and good safety profile, the convenience and ease of administration of mannitol treatment may improve adherence with therapy in these patients…

Written by Cystic Fibrosis News From Medical News Today in: Cystic Fibrosis |

Nov
04
2011
0

New Therapy Marks A Milestone In Fight Against Cystic Fibrosis

Originally posted in Cystic Fibrosis News From Medical News Today

Results of the pivotal Phase 3 clinical trial published in the Nov. 3, 2011 New England Journal of Medicine, find that the oral medication ivacaftor (VX-770) provides major, sustained improvement in lung function, growth and other signs and symptoms for cystic fibrosis (CF) patients…

Written by Cystic Fibrosis News From Medical News Today in: Cystic Fibrosis |

Nov
04
2011
0

New Medication Effectively Treats Underlying Cause Of Cystic Fibrosis

Originally posted in Cystic Fibrosis News From Medical News Today

A new study has confirmed that the drug, ivacaftor (VX-770), significantly improves lung function in some people with cystic fibrosis (CF). The results of the phase III clinical trial study, “A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation,” led by Bonnie W…

Written by Cystic Fibrosis News From Medical News Today in: Cystic Fibrosis |

Nov
03
2011
0

New Drug Candidates Discovered For Cystic Fibrosis And Other Diseases

Originally posted in Cystic Fibrosis News From Medical News Today

A new discovery by Californian scientists may lead to a pharmaceutical breakthrough for a wide range of illnesses that involve the hydration of cells that line the inner surfaces of our body’s organs and tissues…

Written by Cystic Fibrosis News From Medical News Today in: Cystic Fibrosis |

Oct
14
2011
0

Link Between Smoking Cigarettes And Cystic Fibrosis

Originally posted in Cystic Fibrosis News From Medical News Today

New research in The FASEB Journal suggests that cigarette smoke interferes with the Cystic Fibrosis Transmembrane Conductance Regulator protein, leading to dry, sticky mucus and increased infections. If you smoke cigarettes, you have more in common with someone who has cystic fibrosis than you think…

Written by Cystic Fibrosis News From Medical News Today in: Cystic Fibrosis |

Sep
21
2011
0

Cystic Fibrosis: Unraveling A New Regulator

Originally posted in Cystic Fibrosis News From Medical News Today

Cystic fibrosis (CF), a chronic disease that clogs the lungs and leads to life-threatening lung infections, is caused by a genetic defect in a chloride channel called cystic fibrosis transmembrane conductase regulator (CFTR)…

Written by Cystic Fibrosis News From Medical News Today in: Cystic Fibrosis |

Sep
21
2011
0

The Cellular Intricacies Of Cystic Fibrosis

Originally posted in Cystic Fibrosis News From Medical News Today

When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals…

Written by Cystic Fibrosis News From Medical News Today in: Cystic Fibrosis |

Sep
06
2011
0

An ‘Unconventional’ Path To Correcting Cystic Fibrosis

Originally posted in Cystic Fibrosis News From Medical News Today

Researchers have identified an unconventional path that may correct the defect underlying cystic fibrosis, according to a report in the September 2nd issue of the journal Cell, a Cell Press publication. This new treatment dramatically extends the lives of mice carrying the disease-associated mutation…

Written by Cystic Fibrosis News From Medical News Today in: Cystic Fibrosis |

Aug
25
2011
0

Women And The Poor Continuing To Suffer Early Death From Cystic Fibrosis

Originally posted in Cystic Fibrosis News From Medical News Today

A study published on bmj.com indicates, that even though improvements have been made in the last half century for the survival of cystic fibrosis sufferers, females and individuals from socio-economically disadvantaged backgrounds continue to die younger than males and those more privileged in society…

Written by Cystic Fibrosis News From Medical News Today in: Cystic Fibrosis |

Aug
02
2011
0

Why Infection With A Mycobacterium Is Increased By Long-Term Antibiotic Use

Originally posted in Cystic Fibrosis News From Medical News Today

Azithromycin is an antibiotic that also has antiinflammatory properties. It is these antiinflammatory properties that are thought to account for the improvement in clinical outcome observed when patients with chronic lung diseases such as cystic fibrosis are treated long-term with azithromycin…

Written by Cystic Fibrosis News From Medical News Today in: Cystic Fibrosis |

Jul
28
2011
0

$2.1 M NIH Grant To Expand Cystic Fibrosis Research Models

Originally posted in Cystic Fibrosis News From Medical News Today

Case Western Reserve University School of Medicine has received a $2.1 million grant from the National Center for Research Resources, part of the National Institutes of Health (NIH), to expand basic research models for the study of cystic fibrosis (CF). CF is an inherited disease that causes thick, sticky mucus to build up in the lungs and digestive tract…

Written by Cystic Fibrosis News From Medical News Today in: Cystic Fibrosis |

Jul
15
2011
0

New Invasive Diagnostic Procedure Seems To Be Of No Advantage Over Current Standard Procedure In Infants With Cystic Fibrosis

Originally posted in Cystic Fibrosis News From Medical News Today

A comparative study published in July 13 issue of JAMA noticed, treatment based on a new invasive diagnostic procedure for treating cystic fibrosis in infants that involves obtaining and culturing fluid samples from the lungs, when compared with standard diagnostic procedure, did not have a lower prevalence of lung-damaging infection or structural lung injury at 5 years of age…

Written by Cystic Fibrosis News From Medical News Today in: Cystic Fibrosis |

Jul
05
2011
0

New Microarray-On-A-Chip Test For Cystic Fibrosis

Originally posted in Cystic Fibrosis News From Medical News Today

Astra Biotech GmbH is in the pre-launch phase of its newly developed test, based on microarray technology, for rapid simultaneous detection of 25 of the most common mutations causing cystic fibrosis in pan-European populations. This initiative supports Astra Biotech’s aim of facilitating early diagnosis of individuals’ risk factors through innovative assays…

Written by Cystic Fibrosis News From Medical News Today in: Cystic Fibrosis |

Jul
02
2011
0

Ataluren Phase 2 Data In Nonsense Mutation Cystic Fibrosis Published In The European Respiratory Journal

Originally posted in Cystic Fibrosis News From Medical News Today

PTC Therapeutics, Inc. (PTC) announced the publication of data from a Phase 2 study of ataluren, an investigational new drug, in adults with nonsense mutation cystic fibrosis (nmCF) in the European Respiratory Journal…

Written by Cystic Fibrosis News From Medical News Today in: Cystic Fibrosis |

Jun
20
2011
0

Scientists Develop First Ever Drug To Treat ‘Celtic Gene’ In Cystic Fibrosis Sufferers, UK

Originally posted in Cystic Fibrosis News From Medical News Today

An international research team led by Queen’s University have developed a ground breaking treatment for Cystic Fibrosis sufferers. The new drug will benefit sufferers who have the ‘Celtic Gene’, a genetic mutation which is particularly common in Ireland…

Written by Cystic Fibrosis News From Medical News Today in: Cystic Fibrosis |

Jun
19
2011
0

Scientists Develop First Ever Drug To Treat ‘Celtic Gene’ In Cystic Fibrosis Sufferers

Originally posted in Cystic Fibrosis News From Medical News Today

An international research team led by Queen’s University have developed a ground breaking treatment for Cystic Fibrosis sufferers. The new drug will benefit sufferers who have the ‘Celtic Gene’, a genetic mutation which is particularly common in Ireland…

Written by Cystic Fibrosis News From Medical News Today in: Cystic Fibrosis |

Jun
16
2011
0

Lamellar Biomedical Secures Its First Orphan Drug Licence

Originally posted in Cystic Fibrosis News From Medical News Today

Glasgow biopharmaceutical firm, Lamellar Biomedical Ltd, launched four years ago to develop a new class of therapies for the prevention, treatment and control of severe respiratory disease, today announced that their lead clinical candidate LMS-611 for the treatment of patients with cystic fibrosis has received Orphan Drug Designation from the European Commission…

Written by Cystic Fibrosis News From Medical News Today in: Cystic Fibrosis |

Jun
16
2011
0

Abbott Receives FDA Approval For CREON

Originally posted in Cystic Fibrosis News From Medical News Today

Abbott (NYSE: ABT) announced that the U.S. Food and Drug Administration (FDA) has approved an infant-specific dose of CREON

Written by Cystic Fibrosis News From Medical News Today in: Cystic Fibrosis |

Jun
11
2011
0

Insmed’s ARIKACE

Originally posted in Cystic Fibrosis News From Medical News Today

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, announced positive data through six treatment cycles (72 weeks total duration) of its Phase 2 clinical trial program for ARIKACE

Written by Cystic Fibrosis News From Medical News Today in: Cystic Fibrosis |

Jun
11
2011
0

Vertex Plans To Provide Access To Potential CF Therapy VX-770 For Patients With Critical Medical Need

Originally posted in Cystic Fibrosis News From Medical News Today

Vertex Pharmaceuticals Inc. announced a plan to provide VX-770, a CF medicine in development, to people with the G551D mutation who are in critical medical need and may benefit from treatment prior to potential approval of the drug from the U.S. Food and Drug Administration (FDA)…

Written by Cystic Fibrosis News From Medical News Today in: Cystic Fibrosis |

Jun
10
2011
0

Phase 3 STRIVE Study Of VX-770 Showed Durable Improvements In Lung Function And Other Measures Of Disease Among People With A Specific Type Of CF

Originally posted in Cystic Fibrosis News From Medical News Today

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the final results from its pivotal Phase 3 STRIVE study that evaluated VX-770, a medicine in development that targets the defective protein that causes cystic fibrosis (CF). STRIVE was designed to evaluate VX-770 among 161 people 12 years or older with a mutation known as G551D in the CF gene…

Written by Cystic Fibrosis News From Medical News Today in: Cystic Fibrosis |

Jun
10
2011
0

Phase 2 Study Of Two Potential CF Therapies – VX-770 And VX-809 – Shows Promising Results In Patients With Most Common Mutation

Originally posted in Cystic Fibrosis News From Medical News Today

Vertex Pharmaceuticals Incorporated and the Cystic Fibrosis Foundation today announced promising results from an ongoing Phase 2 study evaluating combinations of VX-770 and VX-809, potential medicines designed to treat the defective protein that causes cystic fibrosis. The study enrolled 62 people with two copies of the most common CF mutation, known as Delta F508. The trial lasted three weeks…

Written by Cystic Fibrosis News From Medical News Today in: Cystic Fibrosis |

May
23
2011
0

Researchers Identify Genes Linked To Worsening Of Cystic Fibrosis

Originally posted in Cystic Fibrosis News From Medical News Today

A team of international researchers, including Case Western Reserve University School of Medicine, have discovered regions of the genome that affect the severity of the genetic disease cystic fibrosis (CF), the most common lethal genetic disease affecting children in North America…

Written by Cystic Fibrosis News From Medical News Today in: Cystic Fibrosis |

May
23
2011
0

Consortium Identifies Genome Regions That Could Influence Severity Of Cystic Fibrosis

Originally posted in Cystic Fibrosis News From Medical News Today

A team of researchers, including a number from the University of North Carolina at Chapel Hill School of Medicine, have pinpointed regions of the genome that contribute to the debilitating lung disease that is the hallmark of cystic fibrosis. Their findings provide insight into the causes of the wide variation in lung disease severity experienced by CF patients…

Written by Cystic Fibrosis News From Medical News Today in: Cystic Fibrosis |

May
23
2011
0

Doctor, How Sick Will I Get? It’s All In The Genes

Originally posted in Cystic Fibrosis News From Medical News Today

Johns Hopkins Institute for Genetic Medicine researchers working as part of the North American Cystic Fibrosis Consortium have discovered two regions of the genome that affect the severity of cystic fibrosis, a genetic condition that causes scarring throughout the body, affecting most notably the pancreas and lungs…

Written by Cystic Fibrosis News From Medical News Today in: Cystic Fibrosis |

Bookmark Us!

©Uncle & Drunken Crayfish Productions 2011 www.DrunkenCrayfish.com DrunkenCrayfish

Visit our NEW site at PocketBiker.com
PocketBiker.com Logo

 

TheBuckmaker.com Wordpress Themes | Hosting Provider, Mixed-Tape Free Music